Results 31 to 40 of about 400,631 (298)

The effect of excipients on pharmacokinetic parameters of parenteral drugs [PDF]

open access: yes, 2005
In the pharmaceutical industry, the main goal of early phase in vivo studies is to assess pharmacokinetic properties of a compound in laboratory animals. These data provide a basis for selecting and optimizing drug candidates.
Egger-Heigold, Barbara
core   +1 more source

Investigation of simplified physiologically‐based pharmacokinetic models in rat and human

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
Whole‐body physiologically‐based pharmacokinetic (PBPK) models have many applications in drug research and development. It is often necessary to inform these models with animal or clinical data, updating model parameters, and making the model more ...
Estelle Yau   +4 more
doaj   +1 more source

Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease

open access: yesPharmaceutics, 2023
Substrate reduction therapy (SRT) has been proposed as a new gene therapy for Fabry disease (FD) to prevent the formation of globotriaosylceramide (Gb3). Nanomedicines containing different siRNA targeted to Gb3 synthase (Gb3S) were designed.
Marina Beraza-Millor   +5 more
doaj   +1 more source

Fractal Pharmacokinetics [PDF]

open access: yesComputational and Mathematical Methods in Medicine, 2009
Pharmacokinetics (PK) has been traditionally dealt with under the homogeneity assumption. However, biological systems are nowadays comprehensively understood as being inherently fractal. Specifically, the microenvironments where drug molecules interact with membrane interfaces, metabolic enzymes or pharmacological receptors, are unanimously recognized ...
openaire   +2 more sources

D-optimal designs for pharmacokinetic and combined pharmacokinetic pharmacodynamic models.

open access: yes, 2006
D-optimal designs for pharmacokinetic and combined pharmacokinetic pharmacodynamic ...
Xin. Fang (7990493)
core   +5 more sources

Enhancement of teprenone isomer separation by subcritical fluid chromatography using porous graphitic carbon column

open access: yesJournal of Analytical Science and Technology, 2021
Teprenone is a therapeutic anti-ulcer agent developed in Japan. As described in the Japanese Pharmacopoeia (JP) 17th Edition, gas chromatography/hydrogen flame ionization detection (GC/FID) and high-performance liquid chromatography/ultraviolet detection
Chang Hwa Jin   +4 more
doaj   +1 more source

α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice

open access: yesPharmaceutics, 2021
Fabry disease (FD) is a monogenic X-linked lysosomal storage disorder caused by a deficiency in the lysosomal enzyme α-Galactosidase A (α-Gal A). It is a good candidate to be treated with gene therapy, in which moderately low levels of enzyme activity ...
Julen Rodríguez-Castejón   +6 more
doaj   +1 more source

The PADMET platform - pharmacokinetic characterization of carbohydrate mimetics [PDF]

open access: yes, 2012
More than two decades ago it was realized that drug discovery and development strategies focusing exclusively on affinity enhancement and potency are unsuccessful.
Wittwer, Matthias Beat
core   +1 more source

Role of pharmacists in the management of patients with obesity [PDF]

open access: yesArhiv za farmaciju
Obesity, a chronic disease, is increasingly prevalent worldwide, posing a significant public health challenge. It is often accompanied by comorbidities such as hypertension, cardiovascular disease, dyslipidemia, and diabetes, among others.
Jovanović Marija   +2 more
doaj   +1 more source

Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib

open access: yesPharmaceutics
Background: Asciminib (Scemblix®) is approved for the first-line treatment of adult patients with chronic myeloid leukemia in the chronic phase at 40 mg twice daily (BID) and 80 mg once daily (QD) or 200 mg BID for patients harboring the T315I mutation ...
Ioannis Loisios-Konstantinidis   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy